Amarin Corp Plc (AMRN)

[jomama9231]

The connection is that Judge du had it both ways. She concedes that Tg<500 and > 500 is a similar pt population for purposes of law.

Therefore, reduce it is now relevant bc it has TG < and > 500 (it’s relevant even without her horrible conclusions but let’s just keep going). Further Du used studies with a diff methods than the marine (Eg Kurabayashi not studying TG reduction specifically amongst a ton of examples). Similarly, even tho reduce it was studying CV disease it can likewise still be deemed very relevant.

Lastly, now that reduce it has pts in a relevant patient population and the study itself is relevant, we can use its conclusions. Reduce it showed unexpected benefit in treating pts with Tg> 150 (includes pts > 500 as well) that had CV risk reduction.

Now the connection to strength trial is that the failure there is additive to the above statement. Explained further, strength failing shows the tremendously high level of success reduce it had and how extremely unexpected that benefit was since AZN spent an enormous amount of money pursuing an Epa Dha like product and Failed.